A group meets for a presentation in a glass-walled conference room, while a woman talks on the phone in the background

Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Filter

Nov 2026 | FROM AKERO THERAPEUTICS

Efruxifermin improved fibrosis in participants with MASH cirrhosis and multiple cardiometabolic comorbidities: a post hoc analysis of the SYMMETRY phase 2b trial

Oct 2026 | FROM AKERO THERAPEUTICS

Efruxifermin in MASH with F2/F3 fibrosis: post hoc analysis indicated early histologic features of regression were associated with week 96 fibrosis improvement

Oct 2026 | FROM AKERO THERAPEUTICS

Efruxifermin induced a rapid and direct antifibrotic response that was sustained through 96 weeks in phase 2b trials of participants with MASH and F2/F3 fibrosis or cirrhosis

Aug 2026 | FROM AKERO THERAPEUTICS

Efruxifermin in metabolic dysfunction-associated steatohepatitis: phase 2b results and implications for ongoing phase 3 trials

Aug 2026 | FROM AKERO THERAPEUTICS

Consistent efficacy of efruxifermin across PNPLA3 genotypes in phase 2b trials in MASH

Jun 2026 | FROM AKERO THERAPEUTICS

Efruxifermin Improved Liver Disease and Insulin Sensitivity in Participants with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis in the SYMMETRY Trial

May 2026 | FROM AKERO THERAPEUTICS

Efruxifermin improved digital pathology and noninvasive fibrosis measures in participants with MASH and advanced fibrosis or compensated cirrhosis: analysis of the HARMONY and SYMMETRY phase 2b trials

May 2026 | FROM AKERO THERAPEUTICS

Study design, rationale, and baseline characteristics of the SYNCHRONY Real-World Trial: a phase 3 trial evaluating efruxifermin in participants with MASLD or MASH

Close up of multichannel micropipette filling four small blue centrifuge tubes

Our comprehensive clinical program is designed to evaluate EFX as a potential treatment for MASH.